Cargando…

Hospitalized Children With Familial Hypercholesterolemia and COVID-19: A Case for Preventive Anticoagulation

Detalles Bibliográficos
Autores principales:	Vuorio, Alpo, Raal, Frederick, Kovanen, Petri T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Cardiovascular Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8093379/ https://www.ncbi.nlm.nih.gov/pubmed/33959645 http://dx.doi.org/10.3389/fcvm.2021.657719

Ejemplares similares

Opportunities for preventing further endothelial dysfunction in pregnant COVID-19 patients with familial hypercholesterolemia
por: Vuorio, Alpo, et al.
Publicado: (2022)

Patients with familial hypercholesterolemia and COVID-19: Efficient and ongoing cholesterol lowering is paramount for the prevention of acute myocardial infarction
por: Kovanen, Petri T., et al.
Publicado: (2021)

Hypercholesterolemia and COVID-19: Statins for Lowering the Risk of Venous Thromboembolism
por: Vuorio, Alpo, et al.
Publicado: (2021)

Wildfire smoke exposure and cardiovascular disease—should statins be recommended to prevent cardiovascular events?
por: Vuorio, Alpo, et al.
Publicado: (2023)

Prevention of Cardiovascular Burden in COVID-19 Patients Suffering from Familial Hypercholesterolemia: A Global Challenge
por: Vuorio, Alpo, et al.
Publicado: (2021)

Why continued lipoprotein apheresis is vital for homozygous familial hypercholesterolemia patients with COVID-19
por: Vuorio, Alpo, et al.
Publicado: (2021)

Cholesterol-lowering drugs for high-risk hypercholesterolemia patients with COVID-19 while on Paxlovid™ therapy
por: Vuorio, Alpo, et al.
Publicado: (2022)

Long-Term Cardiovascular and Cerebrovascular Challenges Posed by COVID-19 in Patients With Familial Hypercholesterolemia
por: Vuorio, Alpo, et al.
Publicado: (2022)

Prevention of endothelial dysfunction and thrombotic events in COVID-19 patients with familial hypercholesterolemia
por: Vuorio, Alpo, et al.
Publicado: (2020)

Familial hypercholesterolemia and COVID-19: A menacing but treatable vasculopathic condition
por: Vuorio, Alpo, et al.
Publicado: (2021)

Decreasing the Cholesterol Burden in Heterozygous Familial Hypercholesterolemia Children by Dietary Plant Stanol Esters
por: Vuorio, Alpo, et al.
Publicado: (2018)

Familial hypercholesterolemia and statins in the COVID-19 era: Mitigating the risk of ischemic stroke
por: Vuorio, Alpo, et al.
Publicado: (2021)

Familial hypercholesterolaemia and COVID-19: A two-hit scenario for endothelial dysfunction amenable to treatment
por: Vuorio, Alpo, et al.
Publicado: (2021)

Drug-drug interaction with oral antivirals for the early treatment of COVID-19
por: Vuorio, Alpo, et al.
Publicado: (2023)

Coronary microcirculatory dysfunction in hypercholesterolemic patients with COVID-19: potential benefit from cholesterol-lowering treatment
por: Vuorio, Alpo, et al.
Publicado: (2023)

Monkeypox is a global public health emergency: The role of repurposing cholesterol lowering drugs not to be forgotten
por: Vuorio, Alpo, et al.
Publicado: (2022)

Inhibition of hepatic microsomal triglyceride transfer protein – a novel therapeutic option for treatment of homozygous familial hypercholesterolemia
por: Vuorio, Alpo, et al.
Publicado: (2014)

Comment on: “Prior Treatment with Statins is Associated with Improved Outcomes of Patients with COVID-19: Data from the SEMI-COVID-19 Registry”
por: Vuorio, Alpo, et al.
Publicado: (2021)

Statins as Adjuvant Therapy for COVID-19 to Calm the Stormy Immunothrombosis and Beyond
por: Vuorio, Alpo, et al.
Publicado: (2021)

Mucormycosis and glucose‐regulated protein 78 in COVID‐19: Amenable to statin treatment?
por: Vuorio, Alpo, et al.
Publicado: (2021)

Elevated Lipoprotein(a) and Cerebral Venous Sinus Thrombosis in COVID-19
por: Vuorio, Alpo, et al.
Publicado: (2021)

Continuation of fibrate therapy in patients with metabolic syndrome and COVID-19: a beneficial regime worth pursuing
por: Vuorio, Alpo, et al.
Publicado: (2022)

SARS-CoV-2 reinfection: Adding insult to dysfunctional endothelium in patients with atherosclerotic cardiovascular disease
por: Kovanen, Petri T., et al.
Publicado: (2023)

Editorial: Genetics of Familial Hypercholesterolemia: New Insight
por: Vuorio, Alpo, et al.
Publicado: (2021)

Editorial: Genetics of familial hypercholesterolemia: New insight—Volume II
por: Vuorio, Alpo, et al.
Publicado: (2022)

Applications of machine learning in familial hypercholesterolemia
por: Luo, Ren-Fei, et al.
Publicado: (2023)

Screening and clinical characteristics analysis of familial hypercholesterolemia in a tertiary public hospital
por: Shen, Tianzhou, et al.
Publicado: (2023)

Case report: Unusual coexistence between familial hypercholesterolemia and familial hypobetalipoproteinemia
por: Sasaki, Kei, et al.
Publicado: (2022)

Percutaneous Coronary Intervention in Familial Hypercholesterolemia Is Understudied
por: Ungar, Leo, et al.
Publicado: (2018)

Optimized Treatment of Refractory Hypercholesterolemia in Patients With Atherosclerotic Cardiovascular Disease or Heterozygous Familial Hypercholesterolemia With Alirocumab (OPTIMIZE)
por: Sudano, Isabella, et al.
Publicado: (2022)

Genetic Testing and Risk Scores: Impact on Familial Hypercholesterolemia
por: Sarraju, Ashish, et al.
Publicado: (2019)

Phenotypic vs. genetic cascade screening for familial hypercholesterolemia: A case report
por: Blokhina, Anastasia V., et al.
Publicado: (2022)

Compliance of the aorta in two diseases affecting vascular elasticity, familial hypercholesterolemia and diabetes: a MRI study
por: Soljanlahti, Sami, et al.
Publicado: (2008)

Treatment patterns and use of healthcare resources of patients with atherosclerotic cardiovascular disease and hypercholesterolemia and patients with familial hypercholesterolemia in Spain: Protocol of the Reality study
por: Barrios, Vivencio, et al.
Publicado: (2022)

Correlation of cardiovascular risk predictors with overweight and obesity in patients with familial hypercholesterolemia
por: Wang, Yaodong, et al.
Publicado: (2022)

Aorta of young and middle-aged heterozygous familial hypercholesterolemia patients shows no functional or morphological impairment assessed by MRI
por: Soljanlahti, Sami, et al.
Publicado: (2008)

Prevalence of genetically defined familial hypercholesterolemia and the impact on acute myocardial infarction in Taiwanese population: A hospital-based study
por: Chen, Yen-Ju, et al.
Publicado: (2022)

Preexisting Oral Anticoagulant Therapy Ameliorates Prognosis in Hospitalized COVID-19 Patients
por: Iaccarino, Guido, et al.
Publicado: (2021)

Prevalence and prognosis of molecularly defined familial hypercholesterolemia in patients with acute coronary syndrome
por: Wang, Cheng, et al.
Publicado: (2022)

Modified Lipoproteins Induce Arterial Wall Inflammation During Atherogenesis
por: Lorey, Martina B., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_1scdbm92p7ru2fnqv73fb139ts